Morpholino antisense oligomer targeting human midkine: Its application for cancer therapy

International Journal of Cancer

Volumn 114, Issue 3, 2005, Pages 490-497

  Takei, Yoshifumi ^a   Kadomatsu, Kenji ^a   Yuasa, Kanako ^a   Sato, Waichi ^a   Muramatsu, Takashi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atelocollagen; Heparin binding growth factor; Midkine; Molecular target; Stability; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; MIDKINE; MORPHOLINE DERIVATIVE; NUCLEASE; OLIGODEOXYNUCLEOTIDE; OLIGOMER; PHOSPHOROTHIOIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER THERAPY; COLON CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MEGADOSE; DRUG SCREENING; DRUG STABILITY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN TARGETING; SEROLOGY;

ANIMALS; CELL PROLIFERATION; COLONIC NEOPLASMS; CYTOKINES; DOWN-REGULATION; HUMANS; MALE; MICE; MICE, NUDE; MORPHOLINES; NEOPLASMS; NERVE GROWTH FACTORS; OLIGONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 14044263533     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20781     Document Type: Article

References (45)

1. Roth CM, Yarmush ML. Nucleic acid biotechnology. Annu Rev Biomed Eng 1999;1:265-97.
2. Agrawal S, Mayrand SH, Zamecnik PC, Pederson T. Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides. Proc Natl Acad Sci USA 1990;87:1401-5.
3. Stein CA, Cohen JS. Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Res 1988;48:2659-68.
4. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol 1994;45:932-43.
5. Agrawal S, Temsamani J, Galbraith W, Tang J. Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet 1995;28:7-16.
6. Matsukura M, Shinozuka K, Zon G, Mitsuya H, Reitz M, Cohen JS, Broder S. Phosphorothioate analogs of oligodeoxynucleotides: Inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci USA 1987;84:7706-10.
7. Agrawal S, Goodchild J, Civeira MP, Thornton AH, Sarin PS, Zamecnik PC. Oligodeoxynucleotide phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc Natl Acad Sci USA 1988;85:7079-83.
8. Quartin RS, Brakel CL, Wetmur JG. Number and distribution of methylphosphonate linkages in oligodeoxynucleotides affect exo- and endonuclease sensitivity and ability to form RNase H substrates. Nucleic Acids Res 1989;17:7253-63.
9. Inoue H, Hayase Y, Imura A, Iwai S, Miura K, Ohtsuka E. Synthesis and hybridization studies on two complementary nona(2′-O-methyl)- ribonucleotides. Nucleic Acids Res 1987;15:6131-48.
10. Gao W, Han F, Storm W, Egan W, Cheng Y. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol Pharmacol 1991;41:223-9.
11. Perez JP, Li Y, Stein CA, Majumder S, van Oorschot A, Narayanan R. Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci USA 1994;91:5957-61.
12. Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 1997;7:187-95.
13. Stein D, Foster E, Huang SB, Weller D, Summerton J. A specificity comparison of four antisense types: morpholino, 2′-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev 1997;7:151-7.
14. Summerton J, Stein D, Huang SB, Mattews P, Weller D. Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev 1997;7:63-70.
15. Kadomatsu K, Tomomura M, Muramatsu T. cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis. Biochem Biophys Res Commun 1988;151:1312-8.
16. Muramatsu T. Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem 2002;132:359-71.
17. Kurtz A, Schulte AM, Wellstein A. Pleiotrophin and midkine in normal development and tumor biology. Crit Rev Oncog 1995;6:151-77.
18. Tsutsui J, Kadomatsu K, Matsubara S, Nakagawa A, Hamanoue M, Takao S, Shimazu H, Ohi Y, Muramatsu T. A new family of heparin-binding growth differentiation factors: increased midkine expression in Wilms' tumor and other human carcinomas. Cancer Res 1993;53:1281-5.
19. Garver RI Jr, Chan CS, Milner PG. Reciprocal expression of pleiotrophin and midkine in normal versus malignant lung tissues. Am J Respir Cell Mol Biol 1993;9:463-6.
20. Garver RI Jr, Radford DM, Donis-Keller H, Wick MR, Milner PG. Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer 1994;74:1584-90.
21. Nakagawara A, Milbrandt J, Muramatsu T, Deuel TF, Zhao H, Cnaan A, Brodeur GM. Differential expression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res 1995;55:1792-7.
22. Aridome K, Tsutsui J, Takao S, Kadomatsu K, Ozawa M, Aikou T, Muramatsu T. Increased midkine gene expression in human gastrointestinal cancers. Jpn J Cancer Res 1995;86:655-61.
23. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res 1996;56:2515-8.
24. Kadomatsu K, Hagihara M, Akhter S, Fan QW, Muramatsu H, Muramatsu T. Midkine induces the transformation of NIH3T3 cells. Br J Cancer 1997;75:354-9.
25. Muramatsu H, Muramatsu T. Purification of recombinant midkine and examination of its biological activities: functional comparison of new heparin binding factors. Biochem Biophys Res Commun 1991;177:652-8.
26. Muramatsu H, Shirahama H, Yonezawa S, Maruta H, Muramatsu T. Midkine (MK), a retinoic acid-inducible growth/differentiation factor: immunochemical evidence for the function and distribution. Dev Biol 1993;159:392-402.
27. Qi M, Ikematsu S, Ichihara-Tanaka K, Sakuma S, Muramatsu T, Kadomatsu K. Midkine rescues Wilms' tumor cells from cisplatin-induced apoptosis: regulation of bcl-2 expression by midkine. J Biochem 2000;127:269-77.
28. Maeda N, Ichihara-Tanaka K, Kimura T, Kadomatsu K, Muramatsu T, Noda M. A receptor-like protein-tyrosine phosphatase PTP ς/RPTP β binds a heparin-binding growth factor midkine. Involvement of arginine 78 of midkine in the high affinity binding to PTP ς. J Biol Chem 1999;274:12474-9.
29. Horiba M, Kadomatsu K, Nakamura E, Muramatsu H, Ikematsu S, Sakuma S, Hayashi K, Yuzawa Y, Matsuo S, Kuzuya M, Kaname T, Hirai M, et al. Neointima formation in a restenosis model is suppressed in midkine-deficient mice. J Clin Invest 2000;105:489-95.
30. Qi M, Ikematsu S, Maeda N, Ichihara-Tanaka K, Sakuma S, Noda M, Muramatsu T, Kadomatsu K. Haptotactic migration induced by midkine. Involvement of protein-tyrosine phosphatase ς, mitogen-activated protein kinase, and phosphatidylinositol 3-kinase. J Biol Chem 2001;276:15868-75.
31. Choudhuri R, Zhang H-T, Donnini S, Ziche M, Bicknell R. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 1997;57:1814-9.
32. Ikematsu S, Yano A, Aridome K, Kikuchi M, Kumai H, Nagano H, Okamoto K, Oda M, Sakuma S, Aikou T, Muramatsu H, Kadomatsu K, et al. Serum midkine levels are increased in patients with various types of carcinomas. Br J Cancer 2000;83:701-6.
33. Ikematsu I, Nakagawara A, Nakamura Y, Sakuma S, Wakai K, Muramatsu T, Kadomatsu K. Correlation of elevated level of blood midkine with poor prognostic factors of human neuroblastomas. Br J Cancer 2003;88:1552-26.
34. Takei Y, Kadomatsu K, Matsuo S, Itoh H, Nakazawa K, Kubota S, Muramatsu T. Antisense oligodeoxynucleotide targeted to midkine, a heparin-binding growth factor, suppressed tumorigenicity of mouse rectal carcinoma cells. Cancer Res 2001;61:8486-91.
35. Ochiya T, Takahama Y, Nagahara S, Sumita Y, Hisada A, Itoh H, Nagai Y, Terada M. New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet. Nature Med 1999;5:707-10.
36. Summerton J, Weller D. Uncharged Morpholino-based polymers having phosphorus containing chiral intersubunit linkages. US Patent 5, 185, 444, 1993.
37. Morcos PA. Achieving efficient delivery of morpholino oligos in cultured cells. Genesis 2001;30:94-102.
38. Takei Y, Kadomatsu K, Itoh H, Sato W, Nakazawa K, Kubota S, Muramatsu T. 5′-, 3′-Inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine: its design and application for cancer therapy. J Biol Chem 2002;277:23800-6.
39. Summerton J. Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim Biophys Acta 1999;1489:141-58.
40. Hudziak RM, Barofsky E, Barofsky DF, Weller DL, Huang S-B, Weller DD. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev 1996;6:267-72.
41. Nielsen PE, Egholm M, Berg RH, Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 1991;254:1497-500.
42. Taylor MF, Paulauskis JD, Weller DD, Kobzik L. In vitro efficacy of morpholino-modified antisense oligomers directed against tumor necrosis factor-α mRNA. J Biol Chem 1996;271:17445-52.
43. Honma K, Ochiya T, Nagahara S, Sano A, Yamamoto H, Hirai K, Aso Y, Terada M. Atelocollagen-based gene transfer in cells allows high-throughput screening of gene functions. Biochem Biophys Res Commun 2001;289:1075-81.
44. Ochiya T, Nagahara S, Sano A, Itoh H, Terada M. Biomaterials for gene delivery: Atelocollagen-mediated controlled release of molecular medicines. Curr Gene Ther 2001;1:31-52.
45. Kojima S, Muramatsu H, Amanuma H, Muramatsu T. Midkine enhances fibrinolytic activity of bovine endothelial cells. J Biol Chem 1995;270:9590-6.